Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD; and Ebony R. Hoskins, MD, FACOG, discuss several cases of endometrial cancer using biomarkers to drive treatment decisions.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the evidence for contemporary and emerging biomarker testing strategies in individualizing therapy for patients with endometrial cancer
• Evaluate recent clinical trial data for the use of biomarker-driven therapies in advanced and recurrent endometrial cancer
• Apply shared decision-making strategies to develop personalized treatment plans that reflect molecular findings, patient goals, and access consideration

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from BioNTech; Eisai, Inc.; and Merck & Co, Inc.

Co-Chairs:

Kathleen N. Moore, MD, MS, FASCO

Gynecologic Oncologist, Deputy Director
Fred and Pamela Buffett Cancer Center
University of Nebraska
Omaha, NE

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AADI Bioscience, AbbVie, AstraZeneca, BeOne Medicines, BioNTech, Corcept Therapeutics, Daiichi Sankyo, DualityBio, GSK, ImmunoGen, Incyte, Janssen, Loxo/Eli Lilly and Company, Merck, Pfizer, PMV Pharma, Regeneron, Schrödinger, Verastem Oncology, Whitehawk Therapeutics, Zymeworks; Grant/Research Funding: Allarity Therapeutics, AstraZeneca, Daiichi Sankyo, GSK, Immunocore, Iovance Biotherapeutics, Regeneron, Schrödinger, Verastem Oncology; Royalty or Patent Benefits: UpToDate; Other: American Society of Clinical Oncology Board of Directors

Ritu Salani, MD, MBA

Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Daiichi Sankyo, Eisai, Genmab, Merck, Whitehawk; Royalty or Patent Benefits: UpToDate

Faculty:

Casey Cosgrove, MD

Physician, Associate Professor
Gynecologic Oncology
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Daiichi Sankyo, GSK, Merck; Grant/Research Funding: Regeneron

Ebony R. Hoskins, MD, FACOG

Section Director, Gynecologic Oncology
MedStar Washington Hospital Center
Assistant Professor of Clinical Obstetrics and Gynecology
Georgetown University Medical Center
Washington, DC

Disclosures: Ebony R. Hoskins, MD, FACOG, has no relevant financial relationships with ineligible companies.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on immune-related adverse events and the optimal duration of immunotherapy maintenance for endometrial cancer, go to https://www.gotoper.com/iog26endometrial-activity.

Release Date

June 26, 2026

Expiration Date

June 26, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.